This page shows the latest TxCell news and features for those working in and with pharma, biotech and healthcare.
French biotech TxCell – which focuses on ‘CAR-Treg’ therapies designed to provide finely-tuned immunosuppression for indications like organ transplant and avoid broad immunosuppression that can cause infections and cancer – was
Hopes to start cell-based immunotherapy trials next year. Sangamo has agreed a 72m deal to take control of French biotech TxCell, eyeing a regulatory T cell (Treg) platform that it ... By acquiring TxCell, Sangamo thinks it will be able to start trials
Move follows UK allergy therapy developer Circassia's listing. The return of the biotech initial public offering (IPO) in 2013 was largely a US phenomenon, but France's TxCell is flying ... Ferring is paying 3m upfront for rights to Ovasave, and will be
More from news
Approximately 2 fully matching, plus 1 partially matching documents found.
138.5. TxCell/ Ferring. Collaboration, option, licence. Ovasave - personalised cell-based immunotherapy for IBD (inc Crohn's disease, ulcerative colitis) (p2).
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Prior to his new role, Forte has held roles for Bone Therapeutics, TxCell, the European Medicines Agency, and UCB to name a few.
Forte arrives at Bone Therapeutics with over 20 years of industry experience, most recently as chief operating and medical officer at TxCell and before that as chair of the commercialisation committee
French biotech company TxCell has appointed François Meyer as its executive chairman as it completes a strategic realignment around its CAR-Treg research programmes. ... Stéphane Boissel, CEO of TxCell, said: “TxCell has now completed its strategic
Brings experience from Novartis and ZMKS. Valbonne, France-based biotech TxCell has appointed Dr Li Zhou as vice president of cell engineering with its research department. ... François Meyer, head of research at TxCell, said: “With this key
French biotechnology firm TxCell has appointed Prof Zelig Eshar, Prof Chiara Bonini and Dr Bernard Malissen to its newly-formed scientific advisory board. ... As members of the board, they will be responsible for monitoring and guiding the research and
More from appointments
Approximately 3 fully matching, plus 2 partially matching documents found.
Accession was a born from a passion and a vision. A passion to harness the power of market access to...